Phase I-II study of liposomal vincristine [Marqibo; Hana Biosciences] and dexamethasone in relapsed or refractory acute lymphoblastic leukemia

Trial Profile

Phase I-II study of liposomal vincristine [Marqibo; Hana Biosciences] and dexamethasone in relapsed or refractory acute lymphoblastic leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Vincristine (Primary) ; Dexamethasone
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 17 Jan 2012 Additional lead trial centre and investigator identified and company added as trial sponsor (Talon Therapeutics) as reported by ClinicalTrials.gov.
    • 29 Nov 2010 According to a company media release, Hana Biosciences presented results from this and the RALLY trial at ASH (abstract A2143).
    • 27 Jan 2009 Actual patient numbers added, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top